Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types

SECAUCUS, N.J. and BOSTON, Aug. 7, 2025 /PRNewswire/ — Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for…